Multiple Sklerose

Zusammenfassung

In den letzten Jahren wurden neue Medikamente zur Behandlung der Multiplen Sklerose verfügbar und neue diagnostische Richtlinien herausgegeben. Interessante neue Daten kommen auch von histopathologischen Untersuchungen. Sie verweisen auf heterogene Pathomechanismen, die unter dem Etikett „MS” liegen. Offensichtlich ist die Entzündung nur ein Teil der Pathologie, die auch durch neurodegenerative Prozesse bestimmt wird. Gegenwärtig sind die krankheitsmodifizierenden Medikamente überwiegend beim schubartig remittierenden Verlauf wirksam. Es gibt nur wenig Evidenz bezüglich der sekundären Progression und derzeit keine krankheitsmodifizierende Therapie bei der primär progressiven Form. Deshalb spielen symptomorientierte Behandlungsverfahren bei der MS nach wie vor eine große Rolle.

Summary

Within the last years new drugs for the treatment of Multiple Sclerosis have become available as well as new diagnostic guidelines for MS have been established. Intriguing new data also arise from histopathological studies. They point to heterogenous pathomechanisms that might be hidden behind the label of “MS”. Obviously, inflammation is only one part of the pathology that is also driven by a process of neurodegeneration. Future therapies may focus more individually on the subtypes of the disease. The current disease modifying drugs are predominantly effective during the relapsing remitting course. There is less evidence for the secondary progression and no disease modifying therapy exists for the primary progressive course so far. Symptom-oriented therapies therefore still play an important role in the treatment of MS.

Schlüsselwörter

Multiple Sklerose - Therapie - krankheitsmodifizierende Medikamente - Diagnose

Keywords

Multiple sclerosis - therapy - disease modifying drugs - diagnosis

• Literatur

• 1 Arnold D. Evidence for neuroprotection and remyelination using imaging techniques. Neurology 2007; 68 (Suppl. 03) S83-90.
• 2 Bakshi R, Minagar A, Jainsani Z, Wolinsky J. Imaging of multiple sclerosis: role in neurotherapeutics. Journal of the American Society for Experimental NeuroTherapeutics 2005; 02: 277-303.
• 3 Balcer LJ. et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007; 68: 1299-304.
• 4 Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-68.
• 5 Comi G. et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 19 357: 1576-82.
• 6 Cree BA. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
• 7 Durelli L. et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
• 8 Goodin DS. et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178.
• 9 Hartung HP. et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
• 10 Hartung HP. Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 2005; 252 3 iii44-iii50.
• 11 Jacobs LD. et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group N Engl J Med 2000; 343: 898-904.
• 12 Kobelt G. et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatr 2006; 77: 918-926.
• 13 Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-8.
• 14 Lennon VA. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-12.
• 15 Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004; 56: 308.
• 16 Lucchinetti CF. et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125: 1450-1461.
• 17 McDonald WI. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
• 18 Montalban X. The importance of long-term data in multiple sclerosis. J Neurol 2006; 253 (Suppl. 06) vi9-vi15.
• 19 Panitch H. et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCETrial. Neurology 2002; 59: 1496-506.
• 20 Pittock SJ. et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390-396.
• 21 Polman CH. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
• 22 Polman CH. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria”. Ann Neurol 2005; 58: 840-846.
• 23 Rudick RA. et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
• 24 Sayao AL, Devonshire V, Tremlett H. Longitudinal follow-up of „benign” multiple sclerosis at 20 years. Neurology 2007; 68: 496-500.
• 25 Sorensen PS. et al. Multiple Sclerosis. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005; 12: 817-827.
• 26 Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002; 09: 557-63.
• 27 Tedeschi G. et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280-285.
• 28 Wegner C. et al. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 2006; 67: 960-967.
• 29 Weihe W. Therapie-Leitlinien bei MS: Zu wessen Nutzen?. Deutsches Ärzteblatt 2006; 05: 237.
• 30 Wingerchuk DM. et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
• 31 Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?. Neurology 2007; 68 (Suppl. 03) S72-82.